Business Wire

NY-WOLTERS-KLUWER

15.5.2024 15:01:33 CEST | Business Wire | Press release

Share
Wolters Kluwer redefines Corporate Performance Management with announcement of AI-powered CCH Tagetik Intelligent Platform

Wolters Kluwer, a global leader in information, software, and services for professionals, today announced its AI-powered CCH Tagetik Intelligent Platform, which has been designed to digitally transform the efficiency, accuracy, and strategic ability of the Office of the CFO.

Ralf Gärtner, Senior Vice President & General Manager, Corporate Performance Management (CPM) Solutions at Wolters Kluwer, said: “We are the first to bring to market an intelligent, AI-empowered platform that enhances an entire suite of CPM solutions. We know that GenAI has the potential to enable finance leaders to deliver financial close and planning cycles fifteen times faster than at present1 and we are harnessing that power for our clients. CCH Tagetik Intelligent Platform’s new, state-of-the-art AI functionality empowers CFOs to unlock the answers they need from their data in a fraction of the time to make better informed, faster, strategic decisions.”

The state-of-the-art AI functionality in the CCH Tagetik Intelligent Platform empowers finance professionals to democratize access to meaningful financial data, manage and control massive datasets with unprecedented speed and automation, unlock hidden insights, and improve and expedite decision making. The platform’s new AI-enabled capabilities include:

  • Ask AI, the new “GenAI ally” from CCH Tagetik, is a central focus of this week’s CCH Tagetik inTouch Global User Conference. This innovative functionality, integrated into the CCH Tagetik Intelligent Platform, enables users to receive real-time, visual responses to text- and voice-based natural language queries. Wolters Kluwer estimates that, like other generative AI solutions, Ask AI will drive efficiencies enabling users to spend ten times more resource on value-adding activities including analytics, decision support and innovation2.
  • Intelligent Analytics enables self-service reporting, analytics, dashboarding and visualization. The engine allows users to access data in a new way – rapidly searching through organized information sets to quickly uncover accurate answers to everyday business questions.
  • AI Automapping accelerates data collection and ensures data governance, while new AI Anomaly Detection ensures data integrity by automatically identifying outliers and flagging unusual or abnormal data patterns.
  • Intelligent Disclosure dynamically integrates financial, non-financial, and ESG consolidated numbers with narratives into data-linked reports. This assures finance and business teams that any document, including annual filings, board books, and management presentations, is always accurate.
  • AI Driver-Based Analysis helps users analyze large swaths of data more quickly to identify key business drivers and exponential growth areas.

These new AI capabilities build on existing AI features of CCH Tagetik, like Predictive Intelligence and Transaction Matching, which already empower users to create explainable, insight-driven predictive forecasts, accelerate data reconciliation and improve decision making.

Together, these first-to-market AI innovations reinforce Wolters Kluwer’s commitment to investing in AI to serve and drive the continued digital transformation of the Office of the CFO.

For more information on the latest in AI, please visit the Wolters Kluwer AI Center.

About Wolters Kluwer

Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software solutions and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services.

Wolters Kluwer reported 2023 annual revenues of €5.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,400 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

For more information, visit www.wolterskluwer.com, follow us on LinkedIn, Facebook, YouTube and Instagram.

1 How to elevate finance value through Generative AI (kpmg.com)

2 How to elevate finance value through Generative AI (kpmg.com)

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240515603977/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release

Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b

LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release

The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen

Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release

Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye